Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641062 | 0.85 | CA2 (0.44) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL2597844 | 0.83 | CA2 (0.65) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL15067645 | 0.82 | GAA (0.47) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL1136782 | 0.82 | TSHR (0.53) | CA2TSHRPIK3CAKMT2A | |
| Hydrochloric Acid SCHEMBL11851846 | 0.81 | CA2 (0.62) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL11836830 | 0.81 | CYP3A4 (0.57) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL19180323 | 0.81 | CYP3A4 (0.52) | CYP3A4CA2 | |
| SCHEMBL2434505 | 0.81 | ALDH1A1 (0.64) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| Hydrochloric Acid SCHEMBL6560031 | 0.80 | ALDH1A1 (0.62) | CYP3A4CA2ALDH1A1TSHRHPGD | |
| SCHEMBL7148985 | 0.79 | CA2 (0.70) | CYP3A4CA2TSHRHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312388-A1 | Benzo [F] Isoindoles As EP4 Receptor Agonists | PTGER4, GPR4, PTGER1 | CYP3A4 70/4885CA2 3710/4885ALDH1A1 1617/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | CYP3A4 1910/4885CA2 2321/4885ALDH1A1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.